Radiation Assessment and Dose Adjustment in Interventional Cardiology with Artifical In-telligence

Radiation Assessment and Dose Adjustment in Interventional Cardiology with Artifical In-telligence - RADAR-AI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00039975

Enrollment

300

Registered

2026-04-15

Start date

2026-05-04

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Interventions

Group 1: Arm A: Without AI, with standard dose Group 2: Arm B: With AI and standard dose Group 3: Arm C: With AI and lower dose

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Age = 18 years • Written informed consent

Exclusion criteria

Exclusion criteria: • Lack of written informed consent • Pregnancy or breastfeeding • Age < 18 years • Significant language barrier • Current participation in another cardiology intervention study

Design outcomes

Primary

Measure	Time frame
Evaluation of whether AI-assisted OPTIQ dose control achieves a significant relative dose reduction per procedure while maintaining image quality. The following parameters will be used for this purpose: • Dose area product per procedure • Cumulative initial dose (Air Kerma, Karef) • Fluoroscopy time • Image quality (quantitative) • Image quality (qualitative) • Image usage/use of additional images	—

Measure

Time frame

Evaluation of whether AI-assisted OPTIQ dose control achieves a significant relative dose reduction per procedure while maintaining image quality. The following parameters will be used for this purpose: • Dose area product per procedure • Cumulative initial dose (Air Kerma, Karef) • Fluoroscopy time • Image quality (quantitative) • Image quality (qualitative) • Image usage/use of additional images

—

Secondary

Measure	Time frame
Quality and safety endpoints, subgroup analyses. • Contrast agent consumption and total image sequences used • Total procedure time • Rate of non-diagnostic images/cine runs, re-exposures, or repeat scans • Inter-observer reliability of image quality • Safety endpoints • Subgroup analyses • Feasibility of AI integration	—

Countries

Germany

Contacts

Public ContactBernhard Unsöld

Universitätsklinikum Gießen und Marburg - Standort Gießen

bernhard.unsoeld@uk-gm.de+49 64198542635

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026